At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men.
In Brief
A Phase 4 clinical trial evaluating Tadalafil and Placebo for Obesity. Completed, enrolled 18 participants across 1 site.
Detailed Summary
Obesity is a chronic disease of multifactorial etiology that develops from the interaction of the influence of nutritive , metabolic , cellular and molecular psychological factors. Tadalafil is Is a drug inhibiting the enzyme phosphodiesterase-5 (PDE-5), responsible for inactivating the vasodilator nitric oxide. USING paragraph was mainly treat erectile dysfunction, and recently approved for the treatment of pulmonary hypertension , it is innovative because of its longer life means, provides efficacy after 36 hours and the highest selectivity. The aim of this study is to evaluate the effect of tadalafil on insulin sensitivity and insulin secretion in obese men. The investigators hypothesis is that the administration of tadalafil improve the insulin sensitivity and insulin secretion in obese men.
Study Details
Timeline
Interventions
Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
Calcined magnesia capsules: one per day, at night, during 28 days.